Caterpillar Inc vs Recursion Pharmaceuticals Inc — how do they compare? Caterpillar Inc trades at $941.16 (market cap $429.03B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.75B). The key difference: Caterpillar Inc is far larger — about 245.2× Recursion Pharmaceuticals Inc's market cap, and Caterpillar Inc pays a 0.7% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CAT | RXRX | |
|---|---|---|
Market Cap | $429.03B | $1.75B |
Sector | Industrials | Health |
52-Week High | $1.06K | $6.79 |
52-Week Low | $404.64 | $2.84 |
Enterprise Value | $468.02B | $1.17B |
Dividend Yield | 0.7% | — |
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $933.34, down 2.0% on the day but up 51% year-to-date, reflecting strong momentum from AI-driven infrastructure demand. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $5.54 surpassing expectations by 19%. Valuation metrics remain elevated with a P/E of 46.39 and P/S of 6.18, while profitability remains robust with a 13.33% net margin and 51.35% ROE. Technical indicators show neutral signals with support at $922 and resistance at $943.
Outlook remains positive with analyst consensus pointing to $1,020 price target (9% upside) and 55% buy ratings. Key opportunities include AI data center power demand generating $10.2B in generator sales, while risks include elevated valuation and cyclical exposure to economic conditions. The company's 32nd consecutive dividend increase expected in June supports income investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →